On April 17, 2026, a pair of groundbreaking announcements signaled a bold new chapter in the fight against cancer, with both clinical and technological advances promising to reshape how doctors and scientists approach some of the most stubborn forms of the disease. In the United States and the United Kingdom, the world’s largest clinical trial of CAR-T cell therapy for pediatric solid tumors opened its doors to young patients, while in San Diego, biotech company CREATE Medicines unveiled the first in vivo data for its pioneering all-mRNA platform at the American Association for Cancer Research (AACR) Annual Meeting. Together, these efforts are setting the stage for a future where personalized, less toxic, and more effective cancer treatments may become the norm rather than the exception.
For decades, children diagnosed with solid tumors—such as rhabdomyosarcoma, Ewing sarcoma, and desmoplastic small round cell tumor—have faced daunting odds. According to CURE Today, survival rates for these cancers have barely budged in the past 30 years, and the treatments themselves, originally designed for adults, often leave young survivors with lifelong side effects like learning difficulties and infertility. But hope is on the horizon. The international NexTGen team, funded by Cancer Grand Challenges (a partnership between Cancer Research UK and the US National Cancer Institute), has launched a clinical trial enrolling up to 60 children and young adults across four sites in the US and UK. This study, the largest of its kind, aims to test a new generation of CAR-T cell immunotherapies tailored specifically for solid tumors in younger patients.
CAR-T cell therapy, which reprograms a patient’s own T cells to hunt down and destroy cancer cells, has already revolutionized treatment for pediatric leukemia and lymphoma. However, solid tumors have proven far more resistant, largely due to physical and biological barriers that stymie immune cell infiltration and allow cancer cells to escape detection. The NexTGen team’s approach is a leap forward: by targeting two different cancer markers at once and employing two separate T-cell therapy platforms, researchers hope to break through these defenses and deliver a one-two punch to the tumor’s core.
"This is the world’s largest CAR-T cell trial for pediatric solid tumors to date, aiming to develop more effective treatments with fewer long-term side effects than traditional care," the project’s news release stated. The clinical trial is structured as a "multi-trial" with three parallel arms, operating at Children’s National Hospital in Washington, Dana-Farber Cancer Institute and Boston Children’s Hospital, and the UCL Cancer Institute at Great Ormond Street in the UK. The first two patients—including one in their early 20s—have already begun treatment.
Unlike previous therapies, which often bombard the body with toxic drugs, this new approach seeks to minimize collateral damage. By reprogramming T cells in the lab to specifically recognize cancer cells, the hope is to spare healthy tissue and reduce the harsh, long-term side effects that can shadow survivors for decades. The trial is open to children and young people with relapsed or refractory solid tumors—meaning their cancer has either returned or failed to respond to standard treatments. For many, this represents a last, best hope.
Safety and feasibility are the primary focus at this early stage. As CURE Today reported, “A major goal of the research is to develop treatments that are less toxic than the current standards of care.” Patients and families interested in participating are encouraged to consult with their oncologists about eligibility at one of the four participating sites. The trial’s international scope and the speed at which it has moved from laboratory to clinic are a testament to the urgency felt by researchers and the families they serve.
Meanwhile, at the AACR Annual Meeting in San Diego, CREATE Medicines, Inc. showcased the next frontier in immune cell engineering. The company announced it would present two posters highlighting its in vivo immune cell programming platform, which allows for direct programming of a patient’s immune cells inside the body—no viral components required. This is a significant shift from traditional ex vivo approaches, where cells are modified outside the body and then reintroduced.
CREATE’s platform leverages mRNA and lipid nanoparticles (LNPs) to deliver genetic instructions to T cells, NK cells, and myeloid cells, enabling the body’s own immune system to mount a coordinated attack on cancer. The company’s new RetroT technology, described as an all-RNA genome integration platform, demonstrated in animal models that CAR T cells engineered without double-strand breaks or viral vectors could significantly reduce tumor burden in leukemia. In a colorectal cancer model, the simultaneous engineering of multiple immune cell types led to tumor regression and remodeling of the tumor microenvironment—a promising sign for tackling solid tumors.
Robert Hofmeister, Ph.D., Chief Scientific Officer at CREATE, emphasized the platform’s flexibility and speed: "The work we are presenting at AACR underscores this unique capability of our platform, leveraging our experience in over 50 patients to develop the next generation multi-immune CARs or stably integrated mRNA in vivo therapies. These advances position the platform for near-term development of novel scalable therapies across autoimmune and oncology."
CREATE’s portfolio, already supported by the largest human clinical dataset in the field, is designed to enable rapid iteration from clinical insight to pipeline innovation. The company’s proprietary mRNA-LNP platform supports scalable, repeat-dose, off-the-shelf immunotherapies, a vision that could make advanced cancer treatments more accessible and less burdensome for patients worldwide.
The two poster presentations at AACR are scheduled for April 19 and April 20, 2026, providing the scientific community with an early look at CREATE’s progress and the potential of in vivo cell therapy. More information is available on the AACR Annual Meeting website, and CREATE invites interested parties to follow their updates and contact their business development and media teams for further details.
Both the NexTGen clinical trial and CREATE’s technological advances reflect a larger trend in oncology: the move toward precision medicine, where treatments are tailored not just to the disease, but to the individual. While challenges remain—solid tumors, in particular, have proven a tough nut to crack—the momentum is undeniable. With international collaboration, innovative funding models, and a willingness to rethink old paradigms, the cancer research community is pushing the boundaries of what’s possible.
For families facing a devastating diagnosis, these developments offer more than just scientific progress—they offer hope. As researchers continue to break new ground, the dream of safer, more effective, and more personalized cancer treatments edges closer to reality.